

**** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.****

Juva Life Inc. Provides Update on Delay in Filing Annual Financial Statements

VANCOUVER, BC – May 15, 2024 – **Juva Life Inc.** (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“**Juva**” or the “**Company**”) a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announces that its annual financial statements for the year ended December 31, 2023, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “Annual Financial Filings”) were not filed by the required filing deadline of April 29, 2024 (the “Filing Deadline”).

The Company’s auditors require additional time to complete the audit due to inventory count issues resulting from the Company’s recent reorganization and as a result, the Annual Financial Filings were not filed on or before the Filing Deadline.

The Company is working on the steps required to complete the Annual Financial Filings and expects to be able to file the Annual Financial Filings by June 28, 2024. The Company will provide updates as further information relating to the Annual Financial Filings becomes available.

The Company was approved by the applicable securities regulatory authorities and received a management cease trade order (“MCTO”) imposed against the Chief Executive Officer and Chief Financial Officer of the Company precluding them from trading securities of the Company. The MCTO will be in effect until the Annual Financial Filings are filed and requires that the Annual Financial Filings be filed on or before June 28, 2024.

Until the Annual Financial Filings are filed, the Company intends to issue bi-weekly default status reports in accordance with National Policy 12-203 - Management Cease Trade Orders. The Company intends to satisfy the provisions of the Alternative Information Guidelines during the period it remains in default of the filing requirements. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

On behalf of the board of directors of Juva Life, Inc.

Doug Chloupek, Chief Executive Officer

For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. All statements that address future plans, activities, events or developments that the Company believes, expects or anticipates will or may occur including the Company’s anticipated pipeline and value of current and customer deployments and future opportunities are the management’s best estimates and cannot be guaranteed or relied upon and is forward-looking information. There can be no

assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements in this news release, whether as a result of new information, future events or otherwise, except as required by law.